Lorlatinib

Trade Name: 
Lorbrena
Manufacturer/Distributor: 
Pfizer Canada ULC
Classification: 
Tyrosine kinase inhibitor
Antineoplastic agent
ATC Class: 
L01XE33 - lorlatinib
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2019/02/22
Date Marketed in Canada (yyyy/mm/dd): 
2019/04/22
Presentation: 
Tablet: 25 mg. DIN: 02485966
Tablet: 100 mg. DIN: 02485974
Comments: 
For treatment of adults with ALK-positive non-small cell lung cancer.